Department of Biomedical Engineering, University of Alberta, Edmonton, CANADA.
Rehabilitation Sciences Program, University of British Columbia, Vancouver, CANADA.
Med Sci Sports Exerc. 2020 Feb;52(2):278-286. doi: 10.1249/MSS.0000000000002151.
The purpose of this study was to provide a rationale for "chemotherapy-periodized" exercise by characterizing cyclical variations in fatigue and exercise response across a chemotherapy cycle and comparing exercise adherence during chemotherapy between a prescription that is periodized according to chemotherapy cycle length and a standard linearly progressed prescription.
Women with breast cancer who were prescribed taxane-based chemotherapy were randomly assigned to a supervised aerobic and resistance exercise program after a chemotherapy-periodized exercise prescription (n = 12) or to usual care during chemotherapy (n = 15). Fatigue and steady state exercise responses were assessed in both groups before the first taxane treatment and across the third treatment (i.e., 0-3 d prior and 3-5 d after the third treatment, and 0-3 d before the fourth treatment) to assess cyclical variations. Adherence to the chemotherapy-periodized exercise prescription was compared with adherence to a standard linear prescription from a prior study in a similar population (n = 51).
Fatigue increased from baseline (marginal mean ± standard error: 3.2 ± 0.4) to before the third treatment (4.1 ± 0.4, P = 0.025), then peaked at 3 to 5 d after the third treatment (5.1 ± 0.4, P = 0.001), before recovering before the fourth treatment (4.3 ± 0.5, P = 0.021). The peak in fatigue at 3 to 5 d post-third treatment corresponded to a decrease in steady state exercise oxygen consumption (V˙O2) (P = 0.013). Compared with a standard linear exercise prescription during chemotherapy, a chemotherapy-periodized exercise prescription resulted in higher attendance during the week after chemotherapy (57% ± 30% vs 77% ± 28%, P = 0.04) and overall attendance (63% + 25% vs 78% ± 23%, P = 0.05).
Fatigue and exercise V˙O2 vary across a chemotherapy cycle. A chemotherapy-periodized exercise prescription that accommodates cyclical variations in fatigue may increase adherence to supervised exercise.
本研究旨在为“化疗周期化”运动提供依据,通过描述化疗周期内疲劳和运动反应的周期性变化,并比较根据化疗周期长度制定的运动处方与标准线性递增处方在化疗期间的运动依从性,来为其提供依据。
接受紫杉烷类化疗的乳腺癌患者被随机分配到监督有氧运动和抗阻运动方案后,根据化疗周期长度制定的运动处方(n = 12)或化疗期间的常规护理(n = 15)。在第一次紫杉烷类治疗前和第三次治疗(即第三次治疗前 0-3 天和第三次治疗后 3-5 天,以及第四次治疗前 0-3 天),评估两组的疲劳和稳态运动反应,以评估周期性变化。将根据化疗周期制定的运动处方的依从性与之前在类似人群中进行的一项标准线性处方(n = 51)的依从性进行比较。
疲劳从基线(边缘均值±标准误差:3.2±0.4)增加到第三次治疗前(4.1±0.4,P = 0.025),然后在第三次治疗后 3-5 天达到峰值(5.1±0.4,P = 0.001),然后在第四次治疗前恢复(4.3±0.5,P = 0.021)。第三次治疗后 3-5 天疲劳达到峰值时,稳态运动耗氧量(V˙O2)下降(P = 0.013)。与化疗期间的标准线性运动处方相比,化疗周期化运动处方在化疗后一周内的出席率更高(57%±30%与 77%±28%,P = 0.04),总体出席率更高(63%+25%与 78%±23%,P = 0.05)。
疲劳和运动 V˙O2在化疗周期内发生变化。适应疲劳周期性变化的化疗周期化运动处方可能会提高监督运动的依从性。